The Weekly Checkup · July 21, 2026
The Weekly Checkup: Week of July 13-17, 2026
The Pulse
63 announced transactions this week, the heaviest volume I've logged since the spring. Technology 36, Services 27, and the platform count stayed thin: 6 platform deals against 55 add-ons, plus two reverse mergers on the biotech side. That ratio has been under 15% for most of the summer. I've stopped reading it as buyers pausing. Existing platforms have enough capital and enough pipeline that new platform formation only happens when a sponsor sees a category nobody has claimed, and there aren't many of those left in services.
The listings section is all home care this week. That wasn't a choice, it's what came through intake, so I'm treating it as one market and spending more time than usual on what the broker copy actually says.
🤝 Announced Deals
Upfront equity value: $2.8 billion | $6.75 per share cash plus up to $2.50 per share in CVRs (roughly $1.0 billion of additional potential consideration)
Lilly agreed to acquire AtaiBeckley, whose lead program BPL-003 (mebufotenin benzoate) is an intranasal synthetic 5-MeO-DMT for treatment-resistant depression, carrying Breakthrough Therapy designation with Phase 3 activities underway. Cash consideration is roughly a 26% premium to the prior close and about 40% to the 30-day VWAP. The CVR pays $1.00 on initiation of a Phase 3 for VLS-01, $0.50 on approval and DEA rescheduling of BPL-003 within five years of closing, and $1.00 on approval and DEA rescheduling of VLS-01 within seven years.
My take: Read the CVR terms twice. Two of the three milestones require FDA approval and DEA rescheduling, and those are separate proceedings in separate agencies. 5-MeO-DMT has sat in Schedule I since a 2010 DEA final rule. The mechanics after approval are reasonably well worn: HHS makes a scheduling recommendation and DEA issues an interim final rule, historically inside 90 days, and the reschedule attaches to the approved product rather than the molecule. That is the Epidiolex path. The cautionary version is cannabis, where the rulemaking has been sitting unfinished for two years. So Lilly is not sharing clinical risk with selling shareholders so much as administrative risk, and it priced that risk at fifty cents to a dollar a share with hard outside dates attached. If you advise sellers with controlled-substance assets, that drafting is the negotiation, not the headline number.
Two other things. This is the third Lilly biotech acquisition I've flagged since April, and the profile hasn't changed: late-stage data, a hard indication, a company that would otherwise need to raise. And on the commercial side, a two-hour supervised in-clinic administration almost certainly means a REMS and a certified site network, which is the Spravato model. Somebody has to build and pay for those sites, and the payment arrangements between a manufacturer, a site of care, and the clinicians supervising the session are exactly the kind of thing that needs a defensible fair market value analysis before it goes live.
A Warburg Pincus-led investor group agreed to acquire a controlling interest in PANTHERx Rare, the largest independent rare disease pharmacy in the country, from Nautic Partners, General Atlantic and The Vistria Group. Nautic and management are rolling significant equity. Terms were not disclosed. Centerview and Goldman Sachs advised PANTHERx; J.P. Morgan advised Warburg.
My take: The ownership history is the interesting part. Centene bought PANTHERx in December 2020, sold it eighteen months later in July 2022 alongside Magellan Rx in a combined $2.8 billion transaction, and disclosed ~$1.4 billion of proceeds attributable to PANTHERx at a reported multiple of 20x EBITDA. Trade coverage of this week's deal put the reported 2026 value at more than five times that figure, but a similar multiple, implying explosive growth. For anyone valuing one of these: revenue multiples are close to useless here. Rare and specialty pharmacies book enormous gross revenue against thin gross margins, so 0.3x revenue and 14x EBITDA can describe the same business.
Guardian Dentistry Partners entered a definitive agreement for a majority acquisition of Select Dental Management, adding 38 locations, roughly 130 dentists, more than 30 partner doctors and over 720 team members across eight states and Washington, D.C. Select was founded in 2018. Reported figures put its EBITDA growth at 115% from 2022 to 2024 on practice-level EBITDA margins of about 20%. Guardian funded it by upsizing its existing credit facility with TPG Twin Brook, Morgan Stanley Private Credit and Prudential, and expects to close before the end of Q3.
My take: Two things matter more than the location count. No new control equity and no recap, just more debt from lenders who have been in this credit since 2021. Private credit is open again for dental at platform scale, which is a different market signal than another sponsor writing a check, and it tells you Guardian's existing lenders were comfortable underwriting a target roughly a third the size of the acquirer without repricing the whole capital structure.
Second, the margin disclosure. Practice-level EBITDA of 20% is not platform EBITDA. Load in the management company (regional operations, revenue cycle, marketing, procurement, compliance, IT, the partner equity program) and consolidated margin on a network this size usually lands in the low-to-mid teens. On roughly 38 locations, the difference between 20% and 14% at, say, $1.3 million of revenue per location is on the order of $3 million of EBITDA, which at any credible dental multiple is a nine-figure valuation swing. Buyers who underwrite off practice-level figures without a fully loaded MSO build are the ones who blow up in year two. Structurally this is eight states plus D.C., meaning eight or nine separate corporate practice of medicine and dental ownership analyses and a management services agreement in each.
AMSURG acquired five GI and endoscopy ambulatory surgery centers in the Wake County area, staffed by 15 board-certified gastroenterologists and hepatologists. AMSURG operates more than 250 centers across 34 states and was acquired by Ascension in a $3.9 billion transaction that closed June 4, after the FTC required divestiture of seven centers in overlapping markets. The combined ASC network is roughly 300 facilities.
My take: This is the first acquisition of consequence since Ascension took ownership, and it answers the question people were asking in June. Ascension did not buy AMSURG to hold it flat. Ascension's CEO said at JPM in January that the AmSurg footprint opens roughly 25 new markets, and North Carolina is exactly that kind of market. The valuation consequences are where it gets interesting. A tax-exempt health system now controls the largest GI ASC platform in the country and is still buying physician-owned centers, which puts a set of problems back on the table that the sponsor-owned version of AMSURG handled as routine. Physician ownership in an ASC needs to fit the ASC safe harbor under the Anti-Kickback Statute, and when the controlling owner is tax-exempt, the purchase price paid to physician sellers and the ongoing distributions to physician investors also have to survive private inurement and private benefit review. Every unit needs a supportable fair market value, documented contemporaneously, not a negotiated one.
Worth noting on process: when Ascension acquired AmSurg's parent, the North Carolina ASCs did not go through Certificate of Need review. Counsel asked the CON Section for a determination that an indirect ownership change six or seven corporate levels above the licensees was exempt. That is the kind of detail that never reaches a press release and often reaches the diligence list too late. North Carolina still reviews ASC development under CON, which is precisely why buying operating centers there beats building them, and why that certificate is carrying part of your multiple if you own one. In other news, Community Health Systems took majority control of an Anchorage surgery center the same week.
Avera acquired CNOS, the Center for Neurosciences, Orthopaedics and Spine, based in Dakota Dunes, South Dakota. The group includes more than 100 physicians, advanced practice providers, physical and occupational therapists and athletic trainers across nine specialties and subspecialties, with over 350 total staff, eight clinic locations and outreach to 29 satellite sites. It becomes Avera CNOS effective January 1, 2027.
My take: Read the composition carefully, because "100-plus providers" is not 100 physicians. This is a mid-sized surgical specialty group with a deep ancillary and rehab layer wrapped around it, and the ancillaries are where the valuation and regulatory work concentrates. Therapy services, athletic training, imaging, and any facility interests each need to be valued and papered separately from professional compensation, because Stark analyzes them differently.
The compensation is the main event regardless. When a system employs a surgical group of this size, the transaction value is usually modest next to the aggregate physician compensation committed over the following three to five years, and that compensation is where the exposure sits. Every agreement has to be commercially reasonable and consistent with fair market value without accounting for the volume or value of referrals, which is difficult to document when the strategic logic of the deal is the referral pattern. The other detail is the effective date: announced in mid-July, effective January 1, 2027. Five and a half months is a long runway, and it usually means payer contracting, Medicare enrollment and reassignment across three states, and a compensation redesign that has to be built before anyone signs. If you are advising a group in this position, that work starts before the LOI, not after.
Linden Capital Partners and Audax Private Equity agreed to sell StatLab Medical Products to Leica Biosystems, an operating company of Danaher. Founded in 1976 and based in McKinney, Texas, StatLab manufactures pre-analytical consumables and reagents across the anatomic pathology workflow for laboratory, distribution and OEM customers in the U.S. and Europe. The sponsors partnered with the company in 2021 and completed nine add-on acquisitions during the hold.
My take: A five-year hold, nine add-ons, a shift from domestic to global manufacturing, and an exit to the strategic that sells the instruments those consumables feed. That is the buy-and-build thesis executed the way it is drawn up, and it is worth studying if you own a niche manufacturer. Consumables businesses price above the capital equipment they attach to, for reasons that hold up under diligence: slides, cassettes, stains and reagents get consumed on a schedule the lab does not control, switching means a validation exercise nobody wants to run, and the revenue behaves like a subscription without being sold as one. The OEM channel is the underrated piece, since products embedded in another manufacturer's system are effectively designed in, and that revenue is stickier than anything a sales force wins. Relevant to Issue #2 and the CareDx carve-out: whole-company tools and consumables assets keep clearing well above where carve-outs price, and the gap hasn't narrowed.
I tracked 57 additional transactions this week. Digital health stayed busy (Lyric / Concert in payment accuracy, Raintree / Spike Technologies in revenue cycle, XRHealth / Swing Therapeutics in digital therapeutics), dental added five more beyond Guardian including Beach Point's exit of the largest school-based mobile dental program and SALT Dental Partners in Maryland pediatrics, veterinary saw Zoetis buy a teleradiology platform, and pediatric therapy consolidated further with Pediatrics Plus announcing two Arkansas acquisitions in one release. The complete list, with the financial detail Scope is known for, will be available to premium subscribers when that tier launches.
🏷️ Active Listings: Businesses You Can Actually Buy
Every listing that came through intake this week was home care or home health, so a few words before the five.
The public anchor everyone is pricing off is Kinderhook's take-private of Enhabit, which closed in May at roughly $1.1 billion enterprise value and something close to 10x EBITDA on a 249-location Medicare-certified platform. None of what follows is that, and the multiples should not look like it.
Two structural points apply to all five. A Medicare-certified agency moves its provider number through the CMS 855A change of ownership process, which runs four to twelve months, and if the agency itself changed hands within the prior 36 months, CMS can require full re-enrollment instead of a novation. Brokers know this: one Dallas listing I read this week markets the agency as having "passed the 36-month rule" as a headline feature. Separately, the state license usually does not travel with the business the way buyers assume, and in several states a change of control means the buyer is applying as a new agency under current rules. That is a closing-condition problem, not a diligence footnote.
The other theme running through all ten listings I reviewed: the true meaning of the "cash flow" line can differ greatly from broker to broker. Reported margins ranged from 10% to 58% inside one service line. That spread is not operational. It is definitional, and I've tried to say where I think owner compensation is sitting in each number.
Location: California (6 counties) | Asking Price: $8.4M | Revenue: $13.9M | Adjusted EBITDA: $1.4M | Margin: 10% | Price / Revenue: 0.60x | Price / EBITDA: 6.0x
Multi-location Medicare-certified agency, 410-patient census, 72% Medicare and 28% commercial payer mix. The listing reports gross revenue of $9.9M in 2021, $10.7M in 2022 and $10.9M in 2023, with $1.17M of adjusted EBITDA in 2023, and describes the business as "on pace" for $13.9M and $1.4M of adjusted EBITDA.
My take: Start with the copy, not the numbers. The write-up says year-to-date growth of 16% "through July 31, 2024," and the pace figures are 2024 figures. This is a 2024 marketing document still in circulation, and one aggregator carrying the same listing code shows it as sold. Before anything else, confirm with the broker whether this is live, and if it is, ask for 2025 actuals and 2026 year-to-date. Two full fiscal years have closed since those numbers were written, and CY2026 rate reductions land squarely in the gap.
On comp: this is the one listing of the five where I think the earnings figure is close to a true EBITDA. It is labeled adjusted EBITDA rather than cash flow, the same broker's other California books use the same convention, and the copy says the leadership team is in place across all key functions and expected to stay. That means management is being paid inside the number. What "adjusted" covers is still unstated, so ask for the bridge.
On price: watch the margin, not the multiple. 2023 was 10.7% and the 2024 projection is 10.1%, so revenue grew 27% while margin slipped. Growth bought with cost is worth less than growth that drops through. And 6.0x looks less like a valuation than a house convention. The same broker listed another Northern California agency at $8.7M of revenue and just over $1M of EBITDA for a $6M ask, which is also 6.0x. If you can get the margin from 10% to 14% on this revenue base, you paid about 4.3x and this is a good deal. If 10% is structural in a Medicare-heavy California book, 6.0x is full. Also confirm whether the six-county footprint runs on one provider number with branches or several, because that determines whether you file one CHOW or six.
Location: Texas | Asking Price: $9.64M | Revenue: $6.3M | Cash Flow: $1.93M | CF Margin: 31% | Price / Revenue: 1.53x | Price / Cash Flow: 5.0x
Skilled and non-skilled services, 32 years in operation, 160 employees (10 full-time, 150 part-time), franchise-affiliated, owner operating semi-absentee and selling to pursue another venture. The listing reports gross revenue growth of 27.7% in 2024 and 11.68% in 2025, and describes an "exceptional compliance record with no Medicare clawbacks pending and zero deficiencies pending on past surveys." Buyers must complete an NDA and show proof of funds before speaking with the owner.
My take: The compliance sentence is written carefully and you should read it that way. "No clawbacks pending" and "zero deficiencies pending" describe the current status of open items, which is not the same as a clean survey history or the absence of a prior repayment. Ask for every survey and plan of correction going back five years, plus any ADR, TPE or UPIC correspondence. In Texas that history is obtainable and the answer is usually informative.
On comp: Vested reports "cash flow," which in broker convention means seller's discretionary earnings with owner compensation added back. A semi-absentee owner should carry a small add-back, so if the seller is telling the truth about being hands-off, most of the 31% is operating margin, and 31% is well above what either Medicare-certified skilled or Medicaid attendant care produces on its own. Something has to explain it. Two candidates. The revenue mix may be more episodic Medicare skilled than the "skilled and non-skilled" framing suggests, which would be good news for a buyer. Or the add-backs include the franchise royalty, which a buyer inherits and cannot add back. Royalties of 3% to 5% on $6.3 million are $190,000 to $315,000, and adding an administrator's market salary on top puts normalized margin nearer 20% to 24% and the effective multiple nearer 6x to 7x than 5.0x.
The franchise agreement deserves to be read before the P&L. Franchisors typically hold transfer consent rights, charge transfer fees, impose territory limits and can require the buyer to sign a current-form agreement with worse economics than the seller's legacy terms. Thirty-two years of history is the most valuable line in the listing: seasoned license, reviewable survey record, and no 36-month re-enrollment problem.
Location: Montgomery County, PA | Asking Price: $4.0M | Revenue: $5.0M | Cash Flow: $514,941 | CF Margin: 10% | Price / Revenue: 0.80x | Price / Cash Flow: 7.8x
Skilled and unskilled lines. Medicare certified, CHAP accredited, Medicaid waiver credentialed, and contracted with the major MCOs including Aetna, Blue Cross/Blue Shield and Keystone 65.
My take: The syndicated version of this listing opens with a question the summary version leaves out: "Own a PA Home Care business? Received an MCO contract cancellation letter? Why not consider this combined Home Care and Home Healthcare business," pitching two service lines as a way to make yourself harder for an MCO to drop. That is the whole thesis, and it tells you the seller and the broker both understand that Pennsylvania home care agencies are being cut from networks. It also tells you the buyer being marketed to is a distressed operator, not a platform.
The backdrop supports the concern. Community HealthChoices is mandatory managed long-term services and supports statewide, and the MCO procurement itself is unsettled: in April the Commonwealth Court ordered the Department of Human Services to redo the bidding after losing applicants challenged the 2024 awards. When the plans themselves don't know their five-year position, provider networks get narrowed rather than widened. An agency whose value proposition is its contracts is exposed to precisely that.
On comp: at 10.3% on $5 million, this looks like an operating margin after paying someone to run the business, which is normal for Medicaid waiver home care where the rate is fixed and direct labor runs 75% to 80%. But the figure is reported to the dollar, which usually means it came off a tax return rather than a normalization workbook. If owner compensation is added back inside that $514,941, true EBITDA is lower and 7.8x becomes 10x or worse. Ask for the owner's W-2 and the specific add-back schedule.
I don't get to 7.8x on these numbers. What is being sold is the credential stack, and assembling Medicare certification, CHAP accreditation, waiver credentialing and executed MCO contracts in southeastern Pennsylvania takes years. For a buyer who has to be in that market next quarter, paying for the paperwork is rational. For anyone else it isn't. I'd structure closer to 5x with the credential premium in an earnout tied to contract continuity twelve and twenty-four months after close, and I'd want written confirmation from each MCO that the contract survives a change of control.
Location: Maryland | Asking Price: $2.9M | Revenue: $1,571,969.50 | Cash Flow: $504,010.80 | CF Margin: 32% | Price / Revenue: 1.81x | Price / Cash Flow: 5.8x
Residential Service Agency licensed at Level 3, which permits skilled services delivered by an RN or LPN, RN supervision of aides, and medication management. Billing is predominantly long-term care insurance and private pay. The agency holds a Medicaid contract that it barely uses, and there is no marketing program.
My take: The financials are quoted to the half-dollar, which tells you they came straight off a P&L with nothing normalized. Treat $504,010.80 as a starting point, not an earnings figure. On comp, and this is the crux: at $1.57 million of revenue, an owner may be working in this business full time. Maryland requires RN involvement in an RSA for oversight and care functions, and a Level 3 license makes that requirement heavier. If the owner is the RN, or is the scheduler and case manager, the buyer inherits a job along with the business. A Maryland RN case manager or agency director runs roughly $90,000 to $120,000 loaded. Subtract that and the margin goes from 32% to about 25%, and the multiple goes from 5.8x to roughly 7.4x on a $1.5 million revenue agency with no marketing function. That is expensive.
The licensing point is the one that would change my bid. In Maryland, a sale or transfer that changes who controls the agency means it is treated as a new agency: the buyer applies for a new RSA license at least 45 days ahead and has to comply with the regulations in effect at the time of transfer, and any stock transfer above 25% counts as a sale. You are not acquiring a license, you are qualifying for one, which puts survey readiness and the RN staffing requirement squarely on the closing checklist. Worth knowing that RSAs, unlike Maryland home health agencies, do not require a Certificate of Need, so the barrier to entry is lower than the licensure language makes it sound.
Location: Minneapolis area, Minnesota | Asking Price: $1.5M (real estate included) | Revenue: $750K | Cash Flow: $436K | CF Margin: 58% | Price / Revenue: 2.00x | Price / Cash Flow: 3.4x
Statewide-licensed HCBS provider, fully staffed, high client retention, established referral relationships, with real estate included in the asking price.
My take: The 58% is the number that doesn't survive contact. HCBS is a direct-labor business. Minnesota waiver rates are built through the disability waiver rate system with an explicit staffing component, and a provider delivering services with employed caregivers typically spends 65% to 75% of revenue on direct care wages and payroll taxes before any administrative cost. A 58% cash flow margin is not achievable in that structure. Which means one of three things is true, and diligence is just figuring out which.
One, the owner is personally delivering a meaningful share of billable hours, and the "cash flow" is that labor recharacterized as profit. At $750,000 of revenue this is the most likely answer. Two, the model is shared living or host-home style, where a contracted caregiver household absorbs the labor and the license holder keeps a coordination fee, in which case the margin can look high but the revenue is fragile and tied to specific placements. Three, the number includes an imputed rent add-back because the owner also owns the building.
Run it out. If the owner functions as both designated manager and a working caregiver, replacement costs a manager's salary of roughly $70,000 to $90,000 plus wages for the hours they personally cover. Take $150,000 to $200,000 of combined replacement cost and normalized EBITDA lands between $235,000 and $285,000. Then strip the real estate: if the building is worth $500,000 to $600,000, the operating business is priced around $900,000 to $1.0 million, which is roughly 3.5x to 4.3x normalized earnings rather than the 3.4x on the page. Not unreasonable, but a different deal than the headline. Get an appraisal and price the two assets independently.
The licensing situation is the reason to slow down. Minnesota DHS imposed a temporary moratorium on new 245D licenses effective January 1, 2026, expected to run 24 months, after the state found significant fraud in its Medicaid program. DHS stopped issuing new licenses, stopped accepting applications, and stopped approving added services on existing licenses, with a narrow exception process. Separately, a 245D license is not transferable or assignable, and a change of ownership (including a sale of 100% of the stock or assets) requires a new license application. Put those together and the obvious structure fails: you cannot simply buy this business and apply for a license, because DHS is not issuing them. The workable paths are narrower, slower and require counsel who does this in Minnesota specifically. There is a carve-out for programs located in a home where the license holder resides, which is worth checking against the shared-living question above. In a moratorium market an existing license is worth more than it was a year ago, and the seller may be entitled to some of that premium. Just do not pay it before confirming you can actually take control of the license.
Sign-Off
That's it for Issue #15.
If this was useful, forward it to one person who works in healthcare deals. Still the most valuable thing you can do for the newsletter.
Reply with what worked and what didn't. This week's listings were all home care, so I went deeper on the broker copy and on where owner compensation is hiding in each earnings figure. Tell me whether that was more useful than covering five unrelated businesses.
If you're interested in our healthcare M&A research, or are exploring a healthcare transaction, a valuation engagement, or a services arrangement FMV opinion, reply directly. Scope Research tracks healthcare M&A in a unique way. HealthFMV works with healthcare business owners, health systems, physician groups, and their attorneys on independent valuations for regulatory compliance, M&A, buy-in/buyout, tax, and disputes.
See you next Tuesday.
Will Hamilton, CVA Founder, Scope Research and HealthFMV
The Weekly Checkup is published every Tuesday morning. Written for general informational purposes. Engagements through Scope Research or HealthFMV require a separate agreement.